Excelsior group has been dedicated to specialty medicines and medical examinations in rare diseases for more than 2 decades. In 2016, Excelsior group established a TGF-beta research center and start up new drug development projects to screen new drug candidates of enhancers and inhibitors targeting at TGF-beta activities in various diseases, such as wound healing, cardiovascular diseases, autoimmune diseases, liver cirrhosis, pulmonary fibrosis, neurodegenerative diseases, and cancer treatments. In 2020, Excelsior group is expanding our team in the field of rare diseases and establish a new research center of specific diseases aim at genetic and metabolic disorders in National Biotechnology Research Park, NBRP. In NBRP, we are investing in precision medical testing, epidemiology study, new drug development, and novel therapeutic technologies in various rare diseases. Besides, we are also looking for more strategic alliances with Academia Sinica, National Health Research Institute and leading medical centers in Taiwan. Our aim is to establish a world-class laboratories in the research of TGF-beta and specific diseases and extend our services to Asian populations.